Schonfeld Strategic Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,011	Closed	-$28K	–	3220
2022 Q2	$28K	Buy	3,011 +1,501	+99%	+$14K	﹤0.01%	2280
2022 Q1	$18K	Buy	+1,510	New	+$27K	﹤0.01%	2400
2021 Q1	–	Sell	-1,230	Closed	-$134K	–	2179
2020 Q4	$134K	Buy	+1,230	New	+$112K	﹤0.01%	1410

Other funds holding SYRS

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Schonfeld Strategic Advisors's SYRS Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 3,011 shares — an estimated $28K sold.

Schonfeld Strategic Advisors first reported a position in SYRS in Q4 2020 and held it in 3 quarters. The position peaked at $134K in Q4 2020. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

Schonfeld Strategic Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 3,011 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $28K.
Schonfeld Strategic Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
Schonfeld Strategic Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $134K in Q4 2020.
53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.